Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer – results from the Tumor Profiler Melanoma project
While advances in the understanding of tumor biology through multi-omics profiling hold the promise of substantially improving patient outcomes, the cost implications of such strategies remain unclear. We therefore performed a comparative cost analysis of patients treated either within the Tumor Profiler (TuPro) melanoma project or from a control cohort who received treatment after standard next-generation sequencing testing. After adjustment of cohorts through inverse probability of treatment weighting, we found no evidence of statistically significant differences in total costs between the two cohorts (95% confidence interval -10% to +67%). Importantly, treatment costs (95% confidence interval -28% to +41%) were similar between the two cohorts. In conclusion, we found no evidence that treatment recommendations guided by advanced multi-omics profiling led to significantly higher treatment costs in a Swiss context.
Authors
- Alexander Ring (ORCID: https://orcid.org/0000-0002-0092-1323)
- Laura Boos (ORCID: https://orcid.org/0000-0002-4287-799X)
- Mitchell Paul Levesque (ORCID: https://orcid.org/0000-0001-5902-9420)
- Bettina Sobottka (ORCID: https://orcid.org/0000-0002-0890-5248)
- Nicola Miglino
- Dominik Menges (ORCID: https://orcid.org/0000-0001-5970-1846)
- Benedict Gosztonyi
- Tarun Mehra
- Nora C. Toussaint (ORCID: https://orcid.org/0000-0001-7911-7647)
Institutions
- Roche (Switzerland) (CH)
- University of Bern (CH)
- SIB Swiss Institute of Bioinformatics (CH)
- Bern University of Applied Sciences (CH)
- University of Basel (CH)
- University of Zurich (CH)
- University Hospital of Basel (CH)
- Karolinska Institutet (SE)
- FHNW University of Applied Sciences and Arts Northwestern Switzerland (CH)
- ETH Zurich (CH)
- Roche Pharma AG (Germany) (DE)
- Integrated Oncology (United States) (US)
- University Hospital of Zurich (CH)
- Psychiatry Baselland (CH)
- Life Science Zurich (CH)
- Swiss Data Science Center (CH)
- Department of Biomedicine Basel (CH)
- University Hospital Cologne (DE)
- Kantonsspital Aarau (CH)
- Max Planck Institute for Biology (DE)
- RWTH Aachen University (DE)
- FH Aachen (DE)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1038/s41698-025-01229-5
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- F. Hoffmann-La Roche
- Les Laboratories Pierre Fabre
- Eidgenössische Technische Hochschule Zürich
- Universität Zürich